NCT03492658 is a Phase 4 clinical trial of Abatacept in Rheumatoid Arthritis, sponsored by Leiden University Medical Center.

Who is sponsoring NCT03492658?

NCT03492658 is sponsored by Leiden University Medical Center.

What drugs are being tested in NCT03492658?

Interventions in NCT03492658: Abatacept, Methotrexate.

What condition does NCT03492658 study?

NCT03492658 studies Rheumatoid Arthritis, Rheumatic Diseases.

Is NCT03492658 still recruiting?

NCT03492658 is currently completed. Last updated 17 August 2022.

Last reviewed 2022-08-17 · How we verify

NCT03492658

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)

Completed Phase 4 Last updated 17 August 2022

What this trial tests

Phase 4 trial testing Abatacept in Rheumatoid Arthritis in 46 participants. Completed in 6 April 2022.

Timeline

17 May 2018

Primary endpoint
26 October 2021

6 April 2022

Quick facts

Lead sponsor	Leiden University Medical Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	17 May 2018
Primary completion	26 October 2021
Estimated completion	6 April 2022
Sites	1 location across Netherlands

Drugs / interventions tested

Abatacept (abatacept) — full drug profile →
Methotrexate — full drug profile →

Conditions studied

Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Rheumatic Diseases — all drugs for Rheumatic Diseases →

Sponsor

Leiden University Medical Center

Who can join

18 and older, any sex, with Rheumatoid Arthritis or Rheumatic Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the effect of CTLA4-Ig (abatacept) on phenotype, transcriptional profile, B cell receptor usage and functional parameters of circulating B cells expressing anticitrullinated protein antibodies (ACPA) in patients with early, methotrexate-naïve, ACPA positive rheumatoid arthritis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Citrullination in the pathology of inflammatory and autoimmune disorders: recent advances and future perspectives.
Ciesielski O, Biesiekierska M, Panthu B, Soszyński M, et al · · 2022 · cited 107× · PMID 35079870 · DOI 10.1007/s00018-022-04126-3

Verify or expand the search:

Other trials of Abatacept

Trials testing the same drug.

NCT07366801 — Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus H · Phase 2, PHASE3 · recruiting
NCT06680661 — ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis · Phase 2 · recruiting
NCT06929039 — Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity St · Phase 1 · completed
NCT06008808 — Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release S · Phase 1 · recruiting
NCT03929601 — Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes · Phase 2 · active not recruiting

Other recruiting trials for Rheumatoid Arthritis

Currently open trials in the same condition.

NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting

Other Leiden University Medical Center trials

Trials by the same sponsor.

NCT07312565 — Occurrence of Abdominal Aortic Aneurysms in Patients With Aneurysmal Subarachnoid Hemorrhage · not yet recruiting
NCT07090343 — Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement · Phase 3 · not yet recruiting
NCT07498738 — Making Diabetes Care Fit for Young Adults Living With Type 1 Diabetes: Observations, Reflections and Expert Opinions · NA · not yet recruiting
NCT06545292 — Microsampling for Therapeutic Drug Monitoring of Oral Oncolytics in Oncology Patients · NA · recruiting
NCT07021495 — SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03492658 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Leiden University Medical Center
Last refreshed: 17 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03492658.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing